It was agreed that Bristol-Myers Squibb would acquire Amylin for $5.3 billion in cash and the assumption of $1.7 billion in debt, with AstraZeneca then paying $3.4 billion in cash to Bristol-Myers Squibb, and Amylin being folded into an existing diabetes joint-venture between AstraZeneca and Bristol-Myers Squibb.
По условиям сделки Bristol-Myers Squibb приобретет Amylin за $5,3 млрд наличными и примет на себя обязательства по выплате $1,7 млрд, а AstraZeneca затем выплатит наличными $3,4 млрд Bristol-Myers Squibb, а Amylin продолжит разработку лекарств от диабета для AstraZeneca и Bristol-Myers Squibb.